Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.37 |
| ▸ | SNCA | P37840 | 1/20 | 0.35 |
| ▸ | HPGDS | O60760 | 2/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | GAK | O14976 | 2/20 | 0.31 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.31 |
| ▸ | COQ8A | Q8NI60 | 2/20 | 0.31 |
| ▸ | NLK | Q9UBE8 | 2/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3135407 | 0.81 | CLK4 (0.42) | BRAF | |
| SCHEMBL3223545 | 0.80 | HDAC8 (0.32) | — | |
| SCHEMBL17529630 | 0.79 | MGLL (0.33) | — | |
| SCHEMBL7772437 | 0.79 | TRPV4 (0.42) | GPR35ALDH1A1CYP2A6KDM4E | |
| SCHEMBL15474815 | 0.78 | CYP1A1 (0.33) | — | |
| SCHEMBL28822186 | 0.77 | ALPL (0.35) | ALPL | |
| SCHEMBL2192941 | 0.76 | TRPA1 (0.34) | — | |
| SCHEMBL15475054 | 0.76 | EGFR (0.43) | — | |
| SCHEMBL28260893 | 0.76 | CYP11B1 (0.30) | CYP11B2 | |
| SCHEMBL17514926 | 0.76 | CYP11B1 (0.33) | ARGPR35KDM1ACYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | claimed |
| EP-3071205-B1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS INC (US) | 2020-02-05 | — | — | EP | claimed |
| CN-110294691-A | The synthesis technology of 2- amino -3,5- dinitro cyanophenyl | 沈阳百傲化学有限公司 | 2019-10-01 | — | — | CN | claimed |
| US-10377769-B2 | Benzopiperazine compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-08-13 | — | — | US | claimed |
| US-20180312524-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2018-11-01 | — | — | US | claimed |
| US-10040759-B2 | Substituted azetidinyl compounds as GlyT1 inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-08-07 | — | — | US | claimed |
| US-20170334846-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-11-23 | — | — | US | claimed |
| EP-3215500-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | Dart NeuroScience (Cayman) Ltd. (KY) | 2017-09-13 | — | — | EP | claimed |
| EP-3071205-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | Forma Therapeutics, Inc. (US) | 2016-09-28 | — | — | EP | claimed |
| US-20160257699-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | claimed |
| US-9422281-B2 | Benzopiperazine compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2016-08-23 | — | — | US | claimed |
| WO-2016073420-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2016-05-12 | — | — | WO | claimed |
| US-20150232465-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2015-08-20 | — | — | US | claimed |
| WO-2015074081-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BAIR KENNETH W (US) | 2015-05-21 | — | — | WO | claimed |
| WO-2007135527-A2 | BENZIMIDAZOLYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-29 | — | — | WO | claimed |
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | disclosed |
| WO-2023134708-A1 | THIAZOLOPYRIDYL AMIDE DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | BEIGENE , LTD. (KY) | 2023-07-20 | — | — | WO | disclosed |
| EP-0763524-A1 | Urea and amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prophylactic use | SANKYO COMPANY LIMITED (JP) | 1997-03-19 | — | — | EP | disclosed |
| US-5565449-A | PLATELET AGGREGATION INHIBITORS | GENENTECH, INC. (US) | 1996-10-15 | — | — | US | disclosed |
| US-5391728-A | Bicyclic B-lactams intermediates having a new amino protecting group | ELI LILLY AND COMPANY (US) | 1995-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | CSNK1A1, CSNK1D, CSNK1G1 | AR 2678/4885SNCA 3663/4885HPGDS 845/4885 |
| US-20150232465-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRPF3, BRD7 | AR 346/4885SNCA 4194/4885HPGDS 3471/4885 |
| US-20180312524-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRPF3, BRD7 | AR 346/4885SNCA 4194/4885HPGDS 3471/4885 |
| US-10040759-B2 | Substituted azetidinyl compounds as GlyT1 inhibitors | GLRA1, AGXT, B4GALT1 | AR 2083/4885SNCA 746/4885HPGDS 2569/4885 |
| US-10377769-B2 | Benzopiperazine compositions as BET bromodomain inhibitors | BRD4, BRPF3, BRD7 | AR 346/4885SNCA 4194/4885HPGDS 3471/4885 |
| US-20160257699-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRPF3, BRD7 | AR 346/4885SNCA 4194/4885HPGDS 3471/4885 |
| US-20170334846-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | GLRA1, AGXT, B4GALT1 | AR 2083/4885SNCA 746/4885HPGDS 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.